Study on Reticulocyte Hemoglobin Content (CHr) In Chronic Renal Disease Patients
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 345
- 试验地点
- 1
- 主要终点
- Comparator Agent
研究概览
简要总结
Anemia is a common complication in patients with Chronic Kidney Disease (CKD) due to reduced erythropoietin production, functional and absolute iron deficiency, and inflammation. Early detection and management of anemia are crucial in improving outcomes. Reticulocyte Hemoglobin Content (CHr) is emerging as a sensitive and reliable marker to assess iron availability for erythropoiesis and can serve as an early indicator of anemia in CKD patients.
Early Detection of Iron Deficiency: CHr reflects the hemoglobin content of newly formed reticulocytes, offering a real-time assessment of iron availability for red blood cell production. This makes it will be more responsive to changes in iron status than traditional markers like serum ferritin or transferrin saturation (TSAT).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 盲法
- None
入排标准
- 年龄范围
- 30.00 Year(s) 至 60.00 Year(s)（—）
- 性别
- All
入选标准
- •Chronic Kidney Disease (CKD), stages 2–5
- •Hemoglobin level less than 11 gm /dl
- •Nno Dialysis Patient.
排除标准
- •Active bleeding or recent transfusion within 3 months Malignancy or active inflammation Non CKD hematologic disorders Pregnancy or lactation.
结局指标
主要结局
Comparator Agent
时间窗: nil
Intervention
时间窗: Testing of Reticulocyte Hemoglobin Content For Anemia in CKD Patients
Time to anemia development Hb Less than 13 gdL for men Less than 12 gdL for women in relation to baseline CHr levels
时间窗: 4 weeks
次要结局
- Comparator Agent(nil)
- Intervention(Testing of Reticulocyte Hemoglobin Content For Anemia in CKD Patients)
- Secondary Outcomes Sensitivity & specificity of CHr Less than 29 pg for predicting anemia(Correlation of CHr with Hb ferritin TSAT)
研究者
Safia Hasan
Sardar Bhagwan Singh University